<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1469">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468971</url>
  </required_header>
  <id_info>
    <org_study_id>CK0802.501.1</org_study_id>
    <nct_id>NCT04468971</nct_id>
  </id_info>
  <brief_title>REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia</brief_title>
  <acronym>RESOLVE</acronym>
  <official_title>Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellenkos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellenkos, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced
      moderate-to-severe PNA-ARDS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center, prospective, double-blinded, placebo controlled Phase 1 randomized clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regimen related ≥ grade 3 toxicity within 48 hours of first infusion</measure>
    <time_frame>48 hours</time_frame>
    <description>Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day treatment success, defined as S28</measure>
    <time_frame>28 days</time_frame>
    <description>Alive and not intubated 28 days after the date of first infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>28 days</time_frame>
    <description>Time to extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation improvement</measure>
    <time_frame>11 days</time_frame>
    <description>Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator free days measured at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days</measure>
    <time_frame>28 days</time_frame>
    <description>Organ failure free days measured at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU free days</measure>
    <time_frame>28 days</time_frame>
    <description>ICU free days measured at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality at day 28</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>COVID19</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CK0802: 1x10^8 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CK0802: 3x10^8 cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CK0802</intervention_name>
    <description>Cryopreserved, off the shelf, cord blood derived T regulatory cells</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Expicient</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented to have an RT-PCR-based diagnosis of SARS-CoV-2 infection by RT-PCR

          -  Moderate-to-severe ARDS as defined by the Berlin Criteria: ratio of partial pressure
             of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of 200 mm Hg or
             less assessed with a positive end-expiratory pressure (PEEP) of &gt;5 cm H2O.

          -  Intubated for less than 120 hours

          -  Age ≥18 years

          -  Ability to provide informed consent or duly appointment health care proxy with the
             authority to provide informed consent.

        Exclusion Criteria:

          1. In the opinion of the investigator, unlikely to survive for &gt;48 hours from screening.

          2. Any physical examination findings and/or history of any illness that, in the opinion
             of the study investigator, might confound the results of the study or pose an
             additional risk to the patient by their participation in the study.

          3. Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency
             oscillatory ventilation (HFOV).

          4. Females who are pregnant.

          5. Patients with active bacteremia at start of therapy enrollment or concurrently active
             moderate to severe other infectious which in the opinion of the investigator may
             possibly affect the safety of CK0802 treatment.

          6. Patients who have been intubated for more than 120 hours.

          7. Known hypersensitivity to DMSO or to porcine or bovine protein.

          8. Any end-stage organ disease which in the opinion of the investigator may possibly
             affect the safety of CK0802 treatment.

          9. High dose steroids.

         10. Receiving an investigational cellular therapy agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tara Sadeghi</last_name>
    <phone>7138064787</phone>
    <email>tara.sadeghi@cellenkosinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joby Mathew</last_name>
      <email>jmathe27@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Gladstone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Reyes-Vidal</last_name>
      <phone>212-305-4921</phone>
      <email>csr52@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Darryl Adams</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Mock, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinchie Onyango</last_name>
      <phone>336-716-6591</phone>
      <email>ponyango@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, St Luke's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sree Coimbatore</last_name>
      <phone>281-202-3975</phone>
      <email>coimbatore.sreevidya@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rafael Cardenas</last_name>
      <email>Rafael.CardenasCastillo@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>ARDS</keyword>
  <keyword>CK0802</keyword>
  <keyword>T regulatory cells</keyword>
  <keyword>cord blood</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

